Crinetics Pharmaceuticals Inc Stock News

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shareholders will have a reason to smile today, with the analysts making...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Chiasma (CHMA – Research Report) today and set a price

Janus Henderson Group PLC grew its position in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 0.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exc

As of late, it has definitely been a great time to be an investor in Crinetics Pharmaceuticals, Inc. (CRNX).

After H.C. Wainwright and Oppenheimer gave Otonomy (NASDAQ: OTIC) a Buy rating last month, the company received another Buy, this

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Momenta Pharma

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN

Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endoc

Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocr

Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power, on Tuesday. HIGH

Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocr

Bank of America Corp DE increased its stake in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 14.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund

5AM Venture Management LLC lessened its position in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 21.2% in the 1st quarter, according to its most recent 13F filing with the Securities and E